Anemia Management with Erythropoiesis-Stimulating Agents

Introduction to ESA Therapy

The National Comprehensive Cancer Network recommends a starting dose of 150 Units/kg three times weekly or 40,000 Units weekly subcutaneously for cancer-related anemia, which translates to 11,400 Units per dose (34,200 Units weekly) for a 76 kg patient 1

For a patient with severe anemia, the American Society of Clinical Oncology suggests starting at the lower end of the dosing range (50 Units/kg) to minimize cardiovascular risks, and monitoring closely for signs of thromboembolism, as elderly patients are at higher risk 2

The American Journal of Kidney Diseases recommends checking hemoglobin every 1-2 weeks following initiation of treatment, and with optimal iron stores, expecting a hemoglobin rise of approximately 0.3 g/dL per week 3
The National Comprehensive Cancer Network suggests that if hemoglobin increases by more than 1 g/dL in a 2-week period, the dose should be reduced by 25%, and therapy should be discontinued if no response after 8 weeks despite dose escalation 1

The National Comprehensive Cancer Network recommends considering iron supplementation if iron stores are inadequate, to ensure adequate iron availability for erythropoiesis 1